DERMAL DOSE Sample Clauses

POPULAR SAMPLE Copied 1 times
DERMAL DOSE. Although dermal contact is not expected to represent a significant route of exposure, a simple calculation of potential dose may be performed for construction workers who could potentially contact contaminated groundwater during excavation or trenching activities. The amount of a chemical that a person may absorb due to dermal contact with contaminated environmental media depends on the following factors: o Chemical concentration in water, o Quantity of media in contact with skin, o Skin surface area contacted, o Frequency of exposure o Duration of exposure, and o Bioavailability of the chemical. The following equation identifies the relevant factors in the calculation of dose through the dermal route of exposure: Dermal Dose = Chemical x (10(-3) mg/ug) x (Area) x ET x DAR ------------------------------------------- WT Where: Dermal Dose = Dose received by dermal absorption of contaminants in water (mg/kg) [Water) = Concentration of chemical in water (ug/g, or ppm x 10(-6) 286 Area = Average exposed skin surface area (cm(2))[an average total body skin surface area is 17,535 cm(2) (Snyd▇▇, ▇▇ al., 1975)] ET = Exposure time (minutes) DAR = Dermal absorption rate (ug/cm(2)-min) WT = Average human body weight (70 kg) Table 4-6 identifies the maximum detected concentrations of chemicals in shallow groundwater from the site (Levi▇▇-▇▇▇▇▇▇, ▇▇89a, and McLaren 1989). Ideally, the potential dose from dermal contact with each of these compounds based on a typical concentration in the shallow ground water would be evaluated. However, the needed values relative to uptake rates and acceptable levels of exposure or cancer potency are available for only a few of the compounds. Therefore, an alternative is to examine representative compounds and infer the potential health impacts from exposure to multiple compounds. For the purposes of this assessment, ethylbenzene, a non-carcinogenic compound which was detected in the highest concentration of all the compounds present, and benzene, a carcinogenic chemical will be evaluated.
View SourceView Similar (2)

Related to DERMAL DOSE

  • Supply of Product Salix shall use reasonable efforts to supply the Product during the Co-Promotion Period in sufficient quantities to satisfy the levels of Product sales forecasted in the then current Marketing Plan. Salix shall maintain reasonable inventory levels of the Product in order to ensure their ability to fulfill this obligation. Salix shall have the sole responsibility and right to fill orders with respect to the Product. Altana shall not solicit orders for the Product but, if for any reason, Altana shall receive an order for the Product, Altana shall promptly forward to Salix any such orders. All orders for Product shall be subject to acceptance by Salix, in its sole discretion, which acceptance shall not be unreasonably withheld. Salix may cancel any order for Product at any time after acceptance without incurring any liability to Altana. Salix shall be solely responsible for responding to requests from Target Physicians for individual patients who need the Product but are unable to afford it. Any such request shall be forwarded by Altana to Salix for processing. Salix shall have the sole right and responsibility for establishing and modifying the terms and conditions of the sale of the Product, including (a) the price at which the Product will be sold, (b) whether the Product will be subject to trade or quantity discounts, (c) whether any discount will be provided for payments on accounts receivable, (d) whether the Product will be subject to rebates, returns and allowances or retroactive price reductions, (e) the channels of distribution of the Product, and (f) whether credit [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. is to be granted or refused in connection with any sale of Product. In the event that Salix fails to supply the Product as required pursuant to this Agreement for any reason other than a Force Majeure, which such failure results in lost sales for Altana, the Parties shall meet and attempt to negotiate a mutually agreeable and commercially reasonable solution. If the Parties cannot reach such an agreement within a reasonable period of time, the issue will be dealt with as contemplated under Section 4.4 of this Agreement.

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Product NYISO will provide Energy Resource Interconnection Service and Capacity Resource Interconnection Service to Developer at the Point of Interconnection.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.